AAAAAA

   
Results: 1-10 |
Results: 10
External quality assessment of laboratory performance in analysis of toxicological cases
Authors: Wilson, JF Toseland, PA Capps, NE Sandle, LN Smith, BL Sweeney, G Thomson, AH Watson, ID Williams, J
Citation: Jf. Wilson et al., External quality assessment of laboratory performance in analysis of toxicological cases, FOREN SCI I, 121(1-2), 2001, pp. 27-32
A survey of extraction techniques for drugs of abuse in urine
Authors: Wilson, JF Smith, BL Toseland, PA Watson, ID Williams, J Thomson, AH Capps, NE Sweeney, G Sandle, LN
Citation: Jf. Wilson et al., A survey of extraction techniques for drugs of abuse in urine, FOREN SCI I, 119(1), 2001, pp. 23-27
Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration
Authors: Giles, LJ Jennings, AC Thomson, AH Creed, G Beale, RJ McLuckie, A
Citation: Lj. Giles et al., Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration, CRIT CARE M, 28(3), 2000, pp. 632-637
Expiratory airflow patterns in children and adults with cystic fibrosis
Authors: Williams, EM Madgwick, RG Thomson, AH Morris, MJ
Citation: Em. Williams et al., Expiratory airflow patterns in children and adults with cystic fibrosis, CHEST, 117(4), 2000, pp. 1078-1084
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - Drug-polymer conjugates
Authors: Vasey, PA Kaye, SB Morrison, R Twelves, C Wilson, P Duncan, R Thomson, AH Murray, LS Hilditch, TE Murray, T Burtles, S Fraier, D Frigerio, E Cassidy, J
Citation: Pa. Vasey et al., Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - Drug-polymer conjugates, CLIN CANC R, 5(1), 1999, pp. 83-94
Population pharmacokinetics of aminoglycoside antibiotics in patients withcystic fibrosis
Authors: Campbell, D Thomson, AH Stack, B
Citation: D. Campbell et al., Population pharmacokinetics of aminoglycoside antibiotics in patients withcystic fibrosis, THER DRUG M, 21(3), 1999, pp. 281-288
Childhood empyema
Authors: Thomson, AH Lenney, W
Citation: Ah. Thomson et W. Lenney, Childhood empyema, THORAX, 54(6), 1999, pp. 563-564
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
Authors: Thomson, AH Vasey, PA Murray, LS Cassidy, J Fraier, D Frigerio, E Twelves, C
Citation: Ah. Thomson et al., Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours, BR J CANC, 81(1), 1999, pp. 99-107
Pharmacokinetics and dose requirements of vancomycin in neonates
Authors: Grimsley, C Thomson, AH
Citation: C. Grimsley et Ah. Thomson, Pharmacokinetics and dose requirements of vancomycin in neonates, ARCH DIS CH, 81(3), 1999, pp. F221-F227
Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis
Authors: Hull, J Thomson, AH
Citation: J. Hull et Ah. Thomson, Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis, THORAX, 53(12), 1998, pp. 1018-1021
Risultati: 1-10 |